Prosecution Insights
Last updated: April 19, 2026

Examiner: HEITMEIER, KENDALL NICOLE

Tech Center 1600 • Art Units: 1621

This examiner grants 67% of resolved cases

Performance Statistics

66.7%
Allow Rate
+6.7% vs TC avg
77
Total Applications
+50.0%
Interview Lift
1338
Avg Prosecution Days
Based on 21 resolved cases, 2023–2026

Rejection Statute Breakdown

0%
§101 Eligibility
23.0%
§102 Novelty
26.4%
§103 Obviousness
29.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17773414 MrgprX2 Antagonists and Uses Thereof Final Rejection Dermira, Inc.
17642292 GLUE DEGRADERS AND METHODS OF USE THEREOF Final Rejection NOVARTIS AG
17906089 A COMBINATION THERAPY WITH NIROGACESTAT AND A BCMA-DIRECTED THERAPY AND USES THEREOF Final Rejection SpringWorks Therapeutics Inc.
17801709 POTENT AND SELECTIVE DEGRADERS OF ALK Final Rejection DANA-FARBER CANCER INSTITUTE, INC.
18041058 COMPANION DIAGNOSTIC FOR AXITINIB Non-Final OA The Regents of The University of Michigan
17416876 QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF Final Rejection The Regents of the University of Michigan
17760472 NOVEL IMIDAZOLE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND USE THEREOF Final Rejection INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
17423289 COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER Non-Final OA Board of Trustees of Michigan State University
17802872 COMPOUNDS THAT MODULATE ANTI-TUMOR IMMUNITY AND METHODS OF DOING THE SAME Non-Final OA University of Florida Research Foundation, Incorporated
18017078 S100 PROTEINS AS NOVEL THERAPEUTIC TARGETS IN MYELOPROLIFERATIVE NEOPLASMS Non-Final OA ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
18017422 SALT OF DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Non-Final OA NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD.
18002578 Salts of Compound and Pharmaceutical Compositions Containing the Same Final Rejection Shenzhen Forward Pharmaceuticals Co., Limited.
18127160 BENZAMIDE COMPOUND AND USE THEREOF Non-Final OA WUHAN HUMANWELL INNOVATIVE DRUG RESEARCH AND DEVELOPMENT CENTER LIMITED COMPANY
18270028 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF Non-Final OA SHANGHAI KUNHENG PHARMA-TECH CO., LTD
17921257 METHODS FOR SYNTHESIZING N-(PHENYLSULFONYL)BENZAMIDE COMPOUNDS AND INTERMEDIATES THEREOF Non-Final OA ASCENTAGE PHARMA GROUP CORP LIMITED
17781699 COMBINATION OF IAP INHIBITORS AND PARP OR MEK INHIBITORS OR OTHER CHEMOTHERAPEUTIC AGENTS Non-Final OA Ascentage Pharma Group Corp Limited
17779893 AHR INHIBITORS AND USES THEREOF Non-Final OA PAHR THERAPEUTICS, INC.
17441484 ORALLY ACTIVE SMALL MOLECULE INHIBITOR OF PAI-1 Final Rejection Renascience, Inc.
18249209 DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS Non-Final OA MEDIC Life Sciences Inc.
18028651 PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS SOLID DISPERSIONS AND METHODS OF PREPARATION THEREOF Non-Final OA Shenzhen Pharmacin Co., Ltd.
18042570 QUINOLONE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF Non-Final OA COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN
18002928 NOVEL HETEROARYL-SUBSTITUTED PYRAZINE DERIVATIVES AS PESTICIDES Non-Final OA Elanco Animal Health GmbH
17915817 COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG Non-Final OA TIANJIN JIKUN MEDICAL TECHNOLOGY CO., LTD.
17932200 SELECTIVE P2X3 MODULATORS Final Rejection GlaxoSmithKline Intellectual Property (No.3) Limited
17904677 USE OF CASTALAGIN OR ANALOGS THEREOF FOR ANTI-CANCER EFFICACY AND TO INCREASE THE RESPONSE TO IMMUNE CHECKPOINT INHIBITORS Non-Final OA VAL-CHUM, LIMITED PARTNERSHIP
17800029 COMPOUND FOR TREATING GOUT, PREPARATION METHOD THEREFOR, AND USE THEREOF Final Rejection Huazhong Pharmaceutical Co., Ltd.
17771945 IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 Final Rejection Asana Biosciences, LLC
17770264 COMPOUNDS AND METHODS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS Final Rejection The University of Vermont and State Agriculture College
17633617 TrkB POSITIVE ALLOSTERIC MODULATORS Final Rejection Université Grenoble Alpes
17632437 Chewing Gum Compositions Containing Cannabinoids Non-Final OA ADVANCED FEMALE TECHNOLOGIES LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month